At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Anal Cancer. Completed, enrolled 38 participants across 4 sites.
Detailed Summary
This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnal Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionDec 2021
Study CompletionMar 2023
TodayJul 2026
First PostedSep 30, 2016
Enrollment StartOct 11, 2016
Primary CompletionDec 1, 2021
Study CompletionMar 1, 2023
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.8 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.